The Ministry of Chemicals and Fertilisers has announced an extension to the application deadline for its Production Linked Incentive (PLI) Scheme aimed at boosting domestic manufacturing of Key Starting Materials (KSMs), Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in India.
The Department of Pharmaceuticals has officially extended the submission date for applications under the PLI Scheme from June 14 to July 4 2025. The extension has been issued through Notice No. 31026/16/2020-Policy dated June 16, 2025. This allows eligible pharmaceutical manufacturers additional time to apply under the current incentive round.
The PLI Scheme for KSMs and APIs aims to strengthen India’s pharmaceutical supply chain by encouraging domestic production of essential raw materials. These include critical ingredients used in the formulation of bulk drugs, which are often imported. The scheme offers incentives to approved applicants based on incremental sales and investment.
The Production Linked Incentive (PLI) Scheme for the pharmaceutical sector, backed by a ₹15,000 crore outlay, is driving 55 homegrown projects focused on high-value drugs, including critical therapies for conditions like cancer and diabetes.
In tandem, a separate ₹6,940 crore initiative encourages domestic manufacturing of essential raw materials, such as Penicillin G, to curb reliance on imports. Additionally, a ₹3,420 crore scheme is accelerating the local production of medical devices, including MRI scanners and cardiac implants.
Applications are to be submitted exclusively through the official online portal at https://plibulkdrugs.ifciltd.com. Interested parties can refer to the scheme guidelines and corrigendum documents hosted on https://pharma-dept.gov.in/schemes. The department has clarified that all conditions outlined in its previous notice dated May 14, 2025, remain applicable.
Read More: No Change in UPI Policy: Govt Denies Claims of Imposing MDR Charges on Digital Payments!
The Indian government has extended the deadline for PLI Scheme applications concerning KSMs and APIs to July 4, 2025. The scheme supports the growth of domestic pharmaceutical manufacturing and promotes self-reliance in the bulk drug sector.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Jun 18, 2025, 4:23 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
